Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 3/20 | 0.68 |
| ▸ | KIF11 | P52732 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.41 |
| ▸ | DUT | P33316 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14288491 | 0.87 | KCNN4 (0.63) | KCNN4KIF11LMNAHTTL3MBTL1 | |
| SCHEMBL12264131 | 0.85 | KIF11 (0.74) | KCNN4KIF11TDP1DUTKMT2A | |
| SCHEMBL20644264 | 0.85 | KCNN4 (0.61) | KCNN4KIF11HTTDUTSIGMAR1 | |
| SCHEMBL29788846 | 0.84 | KCNN4 (0.59) | KCNN4KIF11HTTDUTSIGMAR1 | |
| Bromide SCHEMBL31502532 | 0.84 | KCNN4 (0.59) | KCNN4KIF11HTTDUTSIGMAR1 | |
| SCHEMBL14288493 | 0.84 | KCNN4 (0.59) | KCNN4KIF11HTTDUTSIGMAR1 | |
| SCHEMBL12264133 | 0.81 | KIF11 (0.68) | KCNN4KIF11DUTSIGMAR1TAAR1 | |
| SCHEMBL2490805 | 0.81 | KCNN4 (1.00) | KCNN4KIF11DUTTAAR1MAPK1 | |
| SCHEMBL15577798 | 0.81 | KCNN4 (0.67) | KCNN4KIF11LMNAHTTL3MBTL1 | |
| SCHEMBL4403153 | 0.80 | KCNN4 (0.48) | KCNN4KIF11LMNAHTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210187003-A1 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | SAREPTA THERAPEUTICS, INC. | 2021-06-24 | — | — | US | disclosed |
| EP-3784666-A1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | Merck Patent GmbH (DE) | 2021-03-03 | — | — | EP | disclosed |
| CN-108892682-B | Organic fluorescent small molecule film material and application thereof in TATP, DNT and TNT fluorescence detection | 吉林大学 | 2020-11-13 | — | — | CN | disclosed |
| US-20170119638-A1 | MELANOGENESIS INHIBITOR COMPRISING D-PANTOTHENYL ALCOHOL, AND SKIN-WHITENING COSMETIC CONTAINING SAME MELANOGENESIS INHIBITOR | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2017-05-04 | — | — | US | disclosed |
| WO-2010017060-A1 | UREA DERIVATIVES AS ANTIBACTERIAL AGENTS | SCHERING CORPORATION (US) | 2010-02-11 | — | — | WO | disclosed |
| EP-1368315-B1 | METHOD FOR PREPARING AMLODIPINE | HANMI PHARM IND CO LTD (KR) | 2007-10-17 | — | — | EP | disclosed |
| EP-0435749-B1 | Derivatives of 2-aminopyrimidine-4-carboxamide, their preparation and therapeutic use | SYNTHELABO (FR) | 1996-01-10 | — | — | EP | disclosed |
| EP-0480794-A1 | 2-Aminopyrimidine-4-carboxamide derivatives, their preparation and therapeutic use | SYNTHELABO (FR) | 1992-04-15 | — | — | EP | disclosed |
| EP-0342541-A2 | Retroviral protease inhibitors | ABBOTT LABORATORIES (US) | 1989-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119638-A1 | MELANOGENESIS INHIBITOR COMPRISING D-PANTOTHENYL ALCOHOL, AND SKIN-WHITENING COSMETIC CONTAINING SAME MELANOGENESIS INHIBITOR | MC1R, TYR, NAMPT | KCNN4 4094/4885KIF11 3669/4885LMNA 1637/4885 |
| US-20210187003-A1 | EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY | RBM17, UTRN, UPF1 | KCNN4 2392/4885KIF11 2281/4885LMNA 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.